Irvine Scientific ships first products from plant in Tokyo

Published: 24-Aug-2011
Packaging Pharmaceutical

Facility produces animal component-free cell culture media

Irvine Scientific has shipped the first products from its industrial cell culture media production facility in Tokyo to customers in Japan and Asia.

The new facility, located in Saitama prefecture, manufactures animal component-free cell culture media in volume requirements ranging from research use to production of biopharmaceuticals and vaccines. The plant has been commissioned and validated as completely animal component free (ACF).

The new facility, which meets the highest quality cGMP standards, currently occupies 1,720m2 and replicates the production and processes used at the Irvine Scientific’s Santa Ana, CA, US manufacturing facility.

The Tokyo site has state-of-the-art formulation and packaging equipment, and uses continuous milling and blending equipment designed and built to Irvine Scientific specifications. There is room for expansion depending on customer demands.

The Tokyo facility capacity doubles Irvine Scientific’s current powder manufacturing capability at Santa Ana and will bring the total capacity at both sites to more than 1.2 million kilos a year.

Irvine Scientific, a member of JX Holdings group, is a designer, manufacturer and distributor of industrial cell culture, cytogenetic, assisted reproductive technology (ART) and specialist media products. It is a large-scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets.

See more

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Read more
Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant

Trending Articles

  1. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
  2. FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Semaglutide patent cliff: pharma industry braces for impact With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
  4. dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
  5. Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026 Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant
Ingredients

Irvine introduces NK cell expansion medium for immunotherapy and translational research applications

The first chemically defined, animal component-free cell culture medium for natural killer (NK) cells
Manufacturing

Fujifilm completes acquisition of Irvine Scientific Sales Company and IS Japan

With the acquisition of ISUS and ISJ, Fujifilm will now be able to provide a broad product portfolio from biopharmaceuticals to <i>in vitro</i> fertilisation and cell therapy
Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Packaging

PulPac unveils plastic-like fiber caps

The caps will be presented publicly for the first time at interpack 2026, demonstrating how fiber can move into one of the most widely used and technically demanding components in packaging
Pharmaceutical

Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026

Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory

FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths

The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Subscribe now